Get the Stockscreener App
0.6323
3.92%
-0.0258
Mira Pharmaceuticals Inc stock is traded at $0.6323, with a volume of 123.14K.
It is down -3.92% in the last 24 hours and down -12.13% over the past month.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
See More
Previous Close:
$0.6581
Open:
$0.68
24h Volume:
123.14K
Relative Volume:
1.31
Market Cap:
$26.57M
Revenue:
Net Income/Loss:
$-31.37M
P/E Ratio:
-0.4397
EPS:
-1.438
Net Cash Flow:
$-4.23M
1W Performance:
-15.18%
1M Performance:
-12.13%
6M Performance:
-39.78%
1Y Performance:
-64.87%
1-Day Range:
$0.6309
$0.68
1-Week Range:
$0.626
$0.759
52-Week Range:
$0.60
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.6323 | 26.57M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,257.03 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.56 | 615.87B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.42 | 504.37B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.95 | 360.08B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.62 | 286.29B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
MIRA Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | K6S | US60458C1045 - www.marketscreener.com
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - The Manila Times
Earnings Calendar for: - Yahoo Finance
Is Hasbro Stock Underperforming the S&P 500? - barchart.com
What's Behind MIRA Pharmaceuticals, Inc.'s (MIRA) Big Moment in Cannabis Stocks? - Kalkine Media
This Under-the-Radar AI Data Center Stock Just Assigned Its Michigan Campus a Value of Up to $1.25 Billion - Barchart.com
Trump Just Sent Greenland Mines Stock Soaring 370%. How to Play It Here. - Barchart.com
McDonald’s (MCD) Stock Looks Like a Lost Cause — Until You Look at the Data - Barchart.com
Ralph Lauren Stock: Is RL Outperforming the Consumer Cyclical Sector? - Barchart.com
How Is Host Hotels & Resorts’ Stock Performance Compared to Other REIT Stocks? - Barchart.com
CoreWeave Priced an Upsized $3.7 Billion Convertible Note as Capex Spending Spikes. What That Means for CRWV Stock Fans. - Barchart.com
Stocks Retreat as Bond Yields Climb on Fed Rate Hike Fears - Barchart.com
How Is Carnival Corporation Stock Performance Compared to Other Leisure and Entertainment Stocks - Barchart.com
Is Marvell Stock Outperforming the S&P 500? - Barchart.com
Nebius Stock Spikes 4% on Higher Computer Prices. How to Play NBIS Stock Here. - Barchart.com
Why Is Natera (NTRA) Stock Soaring Today - Barchart.com
Stocks Supported as Crude Oil Prices Ease - Barchart.com
APLD’s 250MW Question: The Deal That Could Unlock Applied Digital Stock’s Next Leg Up - Barchart.com
Red Cat CEO Just Sold $1.6 Million of Stock. Wall Street Sees 144% Rally Ahead. - Barchart.com
How Is United Airlines' Stock Performance Compared to Other Global Jets Stocks? - Barchart.com
Is J.B. Hunt Transport Services Stock Outperforming the S&P 500? - Barchart.com
Nebius’s Price Hike Suggests Michael Burry Made a Mistake and Is Shorting the Best Neocloud Stock - Barchart.com
IBM Once Held Nvidia's Spot as Tech's Biggest Name. The Stock Just Crashed 25%. Here's the Comeback Case. - Barchart.com
Stocks Finish Mostly Higher as Crude Prices Fall - Barchart.com
Fluence Energy (FLNC) Stock Trades Down, Here Is Why - Barchart.com
I Sold Micron Before Q2 Earnings and It Fell 23%. Here’s Why I'm Buying Before the Next Report. - Barchart.com
MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com Nigeria
MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com UK
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review - Yahoo Finance
A drug candidate is moving toward its first patient test for nerve pain caused by chemotherapy. MIRA targets Q1 2027. - stocktitan.net
63% of MIRA Pharmaceuticals (MIRA) shares vote to reelect board and back 2026 auditor - stocktitan.net
Seagate Stock Has Already Exploded. Here’s What Could Send It 99% Higher to $1,600. - Barchart.com
Nearly 300 flights are cancelled due to problems in UK air traffic control system, flight monitor Flightradar24 reports - barchart.com
This Under-the-Radar Biopharma Is Moving MIRA-55, a Non-Opioid Pain Drug That Outperformed Morphine Closer to the Clinic - Barchart.com
Mira advances IND-enabling studies of MIRA-55 for pain - BioWorld News
Is Lam Research Stock Outperforming the Nasdaq? - Barchart.com
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com South Africa
MIRA-55 toxicology results advance non-opioid pain program - TipRanks
MIRA Pharmaceuticals reports toxicology data for pain drug candidate - Investing.com
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com UK
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND - GlobeNewswire
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com India
Better Than Nvidia: 3 AI Dividend Stocks Leaving It in the Dust - barchart.com
MIRA (MIRA) Update: Holds Near $0.73 on the Day; Key Range: $0.69 and $0.77 Define the Nearby Reference Levels for the Current SessionInitial Balance - vinanet.vn
MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest ReadingSegment Revenue Breakdown - vinanet.vn
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusBanking Earnings Report - vinanet.vn
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusQuarterly Earnings - careplusvn.com
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusNon-GAAP Earnings - dars.gov.et
MIRA Pharmaceuticals (MIRA) Earnings Date and Reports 2026 - marketbeat.com
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
5.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):